A detailed history of Hrt Financial LP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Hrt Financial LP holds 52,368 shares of ACAD stock, worth $893,921. This represents 0.0% of its overall portfolio holdings.

Number of Shares
52,368
Previous 175,819 70.21%
Holding current value
$893,921
Previous $2.86 Million 71.82%
% of portfolio
0.0%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$15.14 - $19.14 $1.87 Million - $2.36 Million
-123,451 Reduced 70.21%
52,368 $805,000
Q2 2024

Aug 12, 2024

BUY
$14.62 - $18.42 $2.07 Million - $2.61 Million
141,756 Added 416.16%
175,819 $2.86 Million
Q1 2024

May 13, 2024

SELL
$17.79 - $30.86 $4.92 Million - $8.53 Million
-276,499 Reduced 89.03%
34,063 $629,000
Q4 2023

Feb 09, 2024

BUY
$20.78 - $31.77 $5.84 Million - $8.93 Million
281,165 Added 956.44%
310,562 $9.72 Million
Q3 2023

Nov 13, 2023

BUY
$20.84 - $33.47 $612,633 - $983,917
29,397 New
29,397 $612,000
Q1 2023

May 12, 2023

BUY
$16.32 - $20.92 $4.2 Million - $5.38 Million
257,237 New
257,237 $4.84 Million
Q2 2022

Aug 12, 2022

BUY
$13.01 - $27.22 $182,400 - $381,624
14,020 Added 33.46%
55,918 $787,000
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $1.94 Million - $2.54 Million
-92,531 Reduced 68.83%
41,898 $1.01 Million
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $2.26 Million - $3.64 Million
134,429 New
134,429 $3.14 Million
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $2.68 Million - $3.71 Million
-65,259 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$36.42 - $57.0 $1.09 Million - $1.71 Million
-29,948 Reduced 31.46%
65,259 $0
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $3.74 Million - $5.02 Million
95,207 New
95,207 $4.61 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.